Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy
Treatment with VK0214 led to Significant Reductions in Plasma and Tissue Levels of VLCFAs
Good news. ABCD2 making steady progress...
Pretty cool. Thanks so much for sharing!
increased DHA levels in plasma and RBC of the AMN patient. These increased DHA levels may exert a neuro-protective...
inhibiting the unfolded protein response in X-linked adrenoleukodystrophy ncbi.nlm.nih.gov/pmc/articl...
Start a Community